低分子肝素钠联合灯盏花素治疗进展性缺血性脑卒中疗效观察

Observation of Therapeutic Effects of Combination Low Molecular-weight Heparin Sodium with Breviscapine on Progressive Ischemic Stroke

目的:观察低分子肝素联合灯盏花素治疗进展性缺血性脑卒中的疗效。方法:选择135例发病在12h^48h,病情呈进行性加重的进展性缺血性脑卒中患者,随机分为3组,分别接受低分子肝素治疗、灯盏花素治疗、低分子肝素和灯盏花素联合治疗。一疗程后的作为疗效判定,并监测治疗前后血液流变学的变化。结果:一疗程后低分子肝素组总有效率80.0%、联合用药组总有效率88.9%,明显高于灯盏花素组的71.1%,而且治疗前后血流变学的变化亦有显著性的差异,特别以联合用药组的总有效率最高和血流变学变化最明显,同时未发现出血倾向等不良反应。结论:低分子肝素能有效的治疗进展性缺血性脑卒中,与灯盏花素联合使用具有协同作用,临床疗效确切、安全。

Objective： To observe the therapeutic effects of combination of low- molecular- weight heparin sodium with breviseapine on progressive isehemie stroke. Methods： The 135 eases of progressive ischemie stroke （from 12 hours to 48 hours after the onset of the diseasase） were randomly divided into three groups, which accepted treatment of low- molecular - weight heparin sodium, breviseapine and combination of low - molecular- weight heparin sodium with hreviseapine, respectively. After one course of the treatment the therapeutic effects were assessed and, the changes of hemorheolngy were monitored before and after the treatment. Results： After one course of the treatment, the total effect rates were： low molecular heparin group, 80.0% ; combining group, 88.9% ; breviscapine group, 71.1%. The total effect rates of low molecular heparin group and combining group were significandy increased compared with breviscapine group （ in the combining group the effect rate was highest）. The changes of hemorheology of low molecular heparin group and combining group were significandy decreased （in the combining group it was lower）. The adverse reactions were not found such as hemorrhage. Conclusion： low - molecular- weight heparin can effectively treat progressive ischemic stroke; moreover, the its combination with breviseapine has synergism and significant, safe effects of treatment.